Cerus (CERS) AI Stock Analysis

• Market Cap: $345.91M
• Dividend Yield: N/A
• Average Volume (3M): 1.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: 13.03%
• EPS Growth: 21.28%
• Country: US
• Employees: 614
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 192,171,780
• 10 Day Avg. Volume: 2,949,348
• 30 Day Avg. Volume: 1,751,560
• PEG Ratio: 0.99
• Price to Book (P/B): 6.11
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 46.07
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 2.05
• Enterprise Value/Gross Profit: 3.77
• Enterprise Value/Ebitda: -55.91
• 1Y Price Target: $5.00
• Price Target Upside: 177.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.07
• Revenue Forecast (FY): $251.73M

• Rating: 53 Neutral
• Price Target: $1.50 ▼(-16.67% Downside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is driven primarily by improving financial performance (shrinking losses, better leverage, and newly positive operating/free cash flow) and supportive earnings-call momentum (reaffirmed 2026 growth outlook and continued positive adjusted EBITDA). These positives are weighed down by weak technicals (below major moving averages with negative MACD) and limited valuation support due to ongoing losses and no dividend.

Positive Factors

Recurring consumables-driven business model

Cerus’s revenue mix is anchored in repeat consumable kit sales tied to treated blood unit volumes and installed INTERCEPT systems. This creates recurring, volume-linked revenue that scales with treatment adoption, supporting durable topline predictability and long-run unit economics independent of one-off device sales.

Improving cash generation and leverage

Two consecutive years of positive operating and free cash flow signal improved working-capital discipline and self-funded growth capacity. Sustained cash generation reduces refinancing risk, supports ongoing R&D and commercialization investments, and enhances resilience across a 2–6 month horizon and beyond.

Commercial traction: BCA agreement and INT200 rollout

A national group purchasing agreement with BCA materially expands U.S. distribution reach and lowers contracting friction, while CE Mark and INT200 commercial launch broaden product offerings and support international uptake. These structural commercial milestones underpin durable addressable-market expansion and adoption runway.

Negative Factors

Persistent GAAP losses despite improvement

Although margins and revenues have improved materially, trailing GAAP losses mean returns on equity and capital reinvestment remain constrained. Persisting unprofitability limits balance-sheet compounding and could require continued careful cash allocation, weighing on durability of shareholder returns.

Structural margin pressure from tariffs and IFC costs

Management expects product gross margins to trend in the low‑50% range as higher IFC production costs, import tariffs and inflation persist. These structural cost headwinds can compress long-term gross margins, reduce operating leverage from revenue growth, and make EBITDA less predictable quarter-to-quarter.

Regulatory and clinical-timing uncertainty for RBC and RedeS

Key product optionality (RBC approvals and U.S. RedeS trial results) is subject to multi-stage regulatory reviews and late-2026 clinical readouts. Delays or adverse outcomes would postpone revenue diversification from RBCs and could materially affect medium-term growth and margin improvement plans.

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

How the Company Makes Money

Cerus primarily makes money by selling consumables and related system components used to perform INTERCEPT pathogen-reduction treatments, along with revenue associated with deploying and supporting the INTERCEPT platform at blood centers and hospitals. The core recurring revenue stream is the ongoing purchase of INTERCEPT single-use processing sets/kits and chemical components required per treated blood unit, which typically scales with customer treatment volumes. Cerus also generates revenue from device-related sales (e.g., illuminators or other capital equipment used in the process) and from services such as installation, training, maintenance, and customer support where applicable. In addition, Cerus earns revenue through certain licensing, collaboration, or supply/outsourcing arrangements tied to geographic commercialization and/or component manufacturing and distribution; specific counterparties and the quantitative contribution of these arrangements are not available in the prompt and are therefore null.

Cerus Financial Statement Overview

Summary

Business fundamentals are improving but not yet fully proven: revenue has scaled meaningfully (2020 $91.9M to 2025 $206.1M) with mid‑50% gross margins, losses have narrowed sharply (2025 net margin about -7.6%), leverage has declined (debt down to $56.4M in 2025), and operating/free cash flow turned positive in 2024–2025. The main constraint is ongoing GAAP unprofitability and that consistent positive cash generation is only a couple of years old.

Income Statement

Revenue has scaled meaningfully over time (up from $91.9M in 2020 to $206.1M in 2025) and gross margin has remained solid and fairly stable around the mid‑50% range. Losses, however, persist, though profitability is improving: net margin narrowed from roughly -65% (2020) to about -7.6% (2025), and EBITDA losses have also tightened materially. The main weakness is that the business is still not consistently profitable, which keeps earnings quality and visibility below what investors typically want for the sector.

Balance Sheet

Leverage has improved notably, with total debt down to $56.4M in 2025 from about $96–98M in 2023–2024, and debt relative to equity improving to ~0.87x in 2025 (from ~1.75–1.82x in 2023–2024). Equity remains positive ($65.0M) and the asset base is stable-to-growing ($221.9M in 2025). The key weakness is that returns on equity remain negative due to ongoing net losses, which limits balance-sheet compounding despite the healthier capital structure.

Cash Flow

Cash generation has improved materially versus earlier years: operating cash flow and free cash flow were positive in 2024 and 2025 (operating cash flow of $11.4M and free cash flow of $8.5M in both years), a sharp reversal from large cash burn in 2020–2023. Free cash flow also compares favorably to the net loss (free cash flow running at ~75% of the net loss in 2024–2025), suggesting better working-capital and spending discipline. The primary risk is that cash flow consistency is still relatively new (after multiple years of negative cash flow), so durability through cycles remains to be proven.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	206.13M	180.27M	156.37M	162.05M	130.86M
Gross Profit	112.29M	99.52M	86.40M	87.09M	67.38M
EBITDA	-13.43M	-10.02M	-26.34M	-33.52M	-45.99M
Net Income	-15.63M	-20.92M	-37.49M	-42.78M	-54.37M
Balance Sheet
Total Assets	221.86M	200.92M	197.75M	218.09M	237.50M
Cash, Cash Equivalents and Short-Term Investments	82.88M	80.45M	65.85M	102.15M	129.36M
Total Debt	96.95M	98.10M	96.00M	87.24M	87.59M
Total Liabilities	156.89M	144.02M	144.30M	149.53M	151.88M
Stockholders Equity	64.22M	56.15M	52.65M	67.61M	84.62M
Cash Flow
Free Cash Flow	8.52M	8.52M	-47.77M	-27.61M	-34.83M
Operating Cash Flow	11.36M	11.36M	-43.17M	-25.61M	-33.92M
Investing Cash Flow	-8.13M	-8.13M	8.62M	8.46M	12.69M
Financing Cash Flow	4.96M	4.96M	10.67M	4.19M	34.29M

Cerus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Neutral. The current price of 1.8 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 2.26, and above the 200-day MA of 1.70, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 36.67 is Neutral, neither overbought nor oversold. The STOCH value of 14.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CERS.

Cerus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	80 Outperform	$377.53M	19.35	10.87%	―	18.90%	29.22%
BWAY	79 Outperform	$543.52M	23.59	12.01%	―	27.37%	269.84%
TCMD	62 Neutral	$612.58M	34.75	9.26%	―	9.28%	21.00%
MASS	58 Neutral	$227.64M	9.76	13.25%	―	4.49%	3.61%
CERS	53 Neutral	$345.91M	-25.12	-26.42%	―	13.03%	21.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OM	51 Neutral	$61.27M	-0.69	-54.99%	―	4.65%	68.71%

Cerus Corporate Events

Cerus Announces CEO Succession and Executive Compensation Changes

On March 16, 2026, Cerus Corporation announced that Chief Operating Officer Vivek Jayaraman will become president and chief executive officer effective July 1, 2026, succeeding William “Obi” Greenman, who will transition to executive chairman while Jayaraman also joins the board. The leadership change formalizes a planned succession and elevates a long-serving commercial and operations executive with prior experience at TriVascular and Medtronic.

In connection with the promotion, Cerus detailed a new compensation package for Jayaraman that includes a higher base salary, increased bonus opportunities, and equity awards tied to both time-based vesting and performance criteria. The structure of the equity and severance terms, including accelerated vesting and change-in-control protections, underscores the board’s effort to align executive incentives with shareholder value and provide continuity during potential strategic or corporate events.

The most recent analyst rating on (CERS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.

Cerus announces planned board transition as director departs

On January 19, 2026, Cerus Corporation announced that director Timothy L. Moore, whose current term runs until the company’s 2026 annual meeting of stockholders, has notified the board that he will not stand for re-election at that meeting. The company emphasized that Moore’s decision was not due to any disagreement regarding Cerus’s operations, policies or practices, suggesting the change reflects a routine board transition rather than signaling underlying strategic or governance disputes for investors or other stakeholders.

The most recent analyst rating on (CERS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.